13价和23价肺炎球菌疫苗在中老年人中的临床效果:EPIVAC队列研究,2015-2016年
基于西班牙加泰罗尼亚2025730名≥50岁人群的前瞻性队列研究,随访2015年1月1日至2016年12月31日,评估PCV13和PPsV23对肺炎住院的临床效果。多变量Cox回归显示,PCV13与肺炎球菌肺炎风险升高相关(HR 1.52),PPsV23未改变肺炎球菌肺炎风险(HR 1.08,95%CI 0.98-1.19,未达统计学显著)。结论不支持两种疫苗对肺炎的临床获益。
要点
- PCV13接种与肺炎球菌肺炎风险升高相关(HR 1.52,95%CI 1.17-1.97,p=0.002)。
- PPsV23未改变肺炎球菌肺炎风险(HR 1.08,95%CI 0.98-1.19,未达统计学显著)。
- 在老年人、高危和极高危亚组中,接种疫苗也未显现保护效果。
核心结论
- 在儿童普遍接种PCV的当前时代,数据不支持肺炎球菌疫苗(PCV13或PPsV23)对加泰罗尼亚成人肺炎具有临床获益。
研究设计与样本
- 基于人群的前瞻性队列研究,纳入西班牙加泰罗尼亚2025730名≥50岁人群,随访期为2015年1月1日至2016年12月31日。
- 主要结局为肺炎球菌肺炎或全因肺炎住院,主要解释变量为PCV13/PPsV23接种状态,采用多变量Cox回归模型估计疫苗效果,并调整年龄和基线风险状况。
主要发现
- 队列随访共3897151人年,其中PCV13接种17496人,PPsV23接种1551502人。
- 观察到肺炎球菌肺炎3259例(PCV13接种者63例,PPsV23接种者2243例),全因肺炎24079例(PCV13接种者566例,PPsV23接种者17508例)。
- 总体粗发病率(每10万人年)为肺炎球菌肺炎83.6(PCV13接种者360.1,PPsV23接种者144.6),全因肺炎617.9(PCV13接种者3235.0,PPsV23接种者1128.5)。
- 多变量分析中,PCV13与肺炎球菌肺炎风险升高显著相关(HR 1.52,95%CI 1.17-1.97,p=0.002),与全因肺炎风险升高显著相关(HR 1.76,95%CI 1.61-1.92,p<0.001)。
- PPsV23未改变肺炎球菌肺炎风险(HR 1.08,95%CI 0.98-1.19,p=0.132),但轻度增加全因肺炎风险(HR 1.17,95%CI 1.13-1.21,p<0.001);在老年人、高危和极高危亚组中,接种疫苗也未显现保护效果。
临床怎么用
- 原文结论为数据不支持肺炎球菌疫苗对加泰罗尼亚成人肺炎的临床获益,未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical benefits using the 23-valent pneumococcal polysaccharide vaccine (PPsV23) or the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness for both PPsV23 and PCV13 in preventing pneumonia among middle-aged and older adults. METHODS: Population-based cohort study involving 2,025,730 persons ≥50 years in Catalonia, Spain, who were prospectively followed between 01/01/2015 and 31/12/2016. Primary outcomes were hospitalisation from pneumococcal or all-cause pneumonia and main explanatory variable was PCV13/PPsV23 vaccination status. Multivariable Cox regression models were used to estimate vaccination effectiveness adjusted for age and baseline-risk conditions. RESULTS: Cohort members were followed for 3,897,151 person-years (17,496 PCV13 vaccinated and 1,551,502 PPsV23 vaccinated), observing 3259 pneumococcal pneumonias (63 in PCV13 vaccinated, 2243 in PPsV23 vaccinated) and 24,079 all-cause pneumonias (566 in PCV13 vaccinated, 17,508 in PPsV23 vaccinated). Global incidence rates (per 100,000 person-years) were 83.6 for pneumococcal pneumonia (360.1 in PCV13 vaccinated, 144.6 in PPsV23 vaccinated) and 617.9 for all-cause pneumonia (3235.0 in PCV13 vaccinated, 1128.5 in PPsV23 vaccinated). In the multivariable analyses, the PCV13 appeared significantly associated with an increased risk of pneumococcal pneumonia (hazard ratio [HR]: 1.52; 95% confidence interval [CI]: 1.17-1.97; p = 0.002) and all-cause pneumonia (HR: 1.76; 95% CI: 1.61-1.92; p < 0.001) whereas the PPsV23 did not alter the risk of pneumococcal pneumonia (HR: 1.08; 95% CI: 0.98-1.19; p = 0.132) and slightly increased the risk of all-cause pneumonia (HR: 1.17; 95% CI: 1.13-1.21; p < 0.001). In stratified analyses focused on specific target population subgroups (i.e., elderly people, at-risk and high-risk individuals), protective effects of vaccination did not emerge either. CONCLUSION: Data does not support clinical benefits from pneumococcal vaccination (nor PCV13 neither PPsV23) against pneumonia among Catalonian adults in the current era of universal PCV's childhood immunisation.
引用
- Vila-Corcoles A, Hospital I, Ochoa-Gondar O, et al. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016. Vaccine. 2019. PMID: 31759735. doi:10.1016/j.vaccine.2019.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。